Sedana Medical AB (publ) (SEDANA.ST)
SEK 16.0
(0.38%)
SEK 16.0
(0.38%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -59.61 Million SEK | 18.9% |
| 2022 | -73.5 Million SEK | -26.81% |
| 2021 | -57.96 Million SEK | -113.59% |
| 2020 | -27.13 Million SEK | -65.91% |
| 2019 | -16.35 Million SEK | -138.13% |
| 2018 | -6.86 Million SEK | -77.24% |
| 2017 | -3.87 Million SEK | -401.38% |
| 2016 | 1.28 Million SEK | 206.72% |
| 2015 | -1.2 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 20.65 Million SEK | 154.26% |
| 2024 Q2 | -17.21 Million SEK | -183.33% |
| 2024 Q3 | -22.61 Million SEK | -31.39% |
| 2023 Q2 | 1.42 Million SEK | 108.83% |
| 2023 Q1 | -16.12 Million SEK | 55.14% |
| 2023 Q4 | -38.07 Million SEK | -456.35% |
| 2023 Q3 | -6.84 Million SEK | -580.55% |
| 2023 FY | -59.61 Million SEK | 18.9% |
| 2022 Q1 | -18.97 Million SEK | -12.98% |
| 2022 Q2 | -11.14 Million SEK | 41.24% |
| 2022 FY | -73.5 Million SEK | -26.81% |
| 2022 Q3 | -7.44 Million SEK | 33.22% |
| 2022 Q4 | -35.94 Million SEK | -382.75% |
| 2021 Q2 | -17.28 Million SEK | -92.89% |
| 2021 FY | -57.96 Million SEK | -113.59% |
| 2021 Q1 | -8.96 Million SEK | 24.18% |
| 2021 Q4 | -16.79 Million SEK | -12.55% |
| 2021 Q3 | -14.92 Million SEK | 13.7% |
| 2020 Q4 | -11.82 Million SEK | 11.93% |
| 2020 FY | -27.13 Million SEK | -65.91% |
| 2020 Q3 | -13.42 Million SEK | -273.3% |
| 2020 Q2 | -3.59 Million SEK | -311.51% |
| 2020 Q1 | 1.7 Million SEK | 125.28% |
| 2019 Q3 | -4.93 Million SEK | -186.59% |
| 2019 Q2 | -1.72 Million SEK | 41.99% |
| 2019 Q4 | -6.72 Million SEK | -36.19% |
| 2019 FY | -16.35 Million SEK | -138.13% |
| 2019 Q1 | -2.97 Million SEK | 12.02% |
| 2018 Q1 | -87.02 Thousand SEK | -2380.79% |
| 2018 Q2 | -846.75 Thousand SEK | -872.99% |
| 2018 Q3 | -2.55 Million SEK | -202.19% |
| 2018 Q4 | -3.37 Million SEK | -31.96% |
| 2018 FY | -6.86 Million SEK | -77.24% |
| 2017 Q2 | -510.83 Thousand SEK | 5.75% |
| 2017 Q3 | -2.81 Million SEK | -451.84% |
| 2017 Q4 | -3508.00 SEK | 99.88% |
| 2017 Q1 | -542 Thousand SEK | -159.96% |
| 2017 FY | -3.87 Million SEK | -401.38% |
| 2016 Q1 | 1.06 Million SEK | 0.0% |
| 2016 FY | 1.28 Million SEK | 206.72% |
| 2016 Q4 | 903.98 Thousand SEK | 275.32% |
| 2016 Q2 | -922.8 Thousand SEK | -186.81% |
| 2016 Q3 | 240.85 Thousand SEK | 126.1% |
| 2015 FY | -1.2 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.83 Million SEK | 23.416% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 157.596% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 157.596% |
| Arcoma AB | 2.56 Million SEK | 2424.961% |
| Bactiguard Holding AB (publ) | -138.38 Million SEK | 56.922% |
| BICO Group AB (publ) | -835.7 Million SEK | 92.867% |
| Boule Diagnostics AB (publ) | 24.97 Million SEK | 338.668% |
| CellaVision AB (publ) | 130.3 Million SEK | 145.747% |
| Clinical Laserthermia Systems AB (publ) | -79.79 Million SEK | 25.291% |
| Chordate Medical Holding AB (publ) | -29.18 Million SEK | -104.244% |
| C-Rad AB (publ) | 35.52 Million SEK | 267.784% |
| Duearity AB (publ) | -26.19 Million SEK | -127.614% |
| Dignitana AB (publ) | -17.36 Million SEK | -243.328% |
| Episurf Medical AB (publ) | -94.8 Million SEK | 37.118% |
| Getinge AB (publ) | 2.41 Billion SEK | 102.471% |
| Scandinavian Real Heart AB (Publ) | -67.97 Million SEK | 12.306% |
| Iconovo AB (publ) | -45.89 Million SEK | -29.891% |
| Integrum AB (publ) | 4.03 Million SEK | 1578.297% |
| Luxbright AB (publ) | -25.37 Million SEK | -134.923% |
| Mentice AB (publ) | -2.81 Million SEK | -2016.152% |
| OssDsign AB (publ) | -130.49 Million SEK | 54.318% |
| Paxman AB (publ) | 8.33 Million SEK | 815.63% |
| Promimic AB (publ) | -9.22 Million SEK | -546.411% |
| Qlife Holding AB (publ) | -159.95 Million SEK | 62.732% |
| SciBase Holding AB (publ) | -55.58 Million SEK | -7.245% |
| ScandiDos AB (publ) | -14.64 Million SEK | -306.991% |
| Sectra AB (publ) | 428.38 Million SEK | 113.915% |
| Senzime AB (publ) | -134.14 Million SEK | 55.563% |
| SpectraCure AB (publ) | -20.44 Million SEK | -191.63% |
| Stille AB | 26.64 Million SEK | 323.718% |
| Vitrolife AB (publ) | -3.85 Billion SEK | 98.452% |
| Xvivo Perfusion AB (publ) | 91.82 Million SEK | 164.923% |